S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Corvus Pharmaceuticals (CRVS) Competitors

$1.64
-0.10 (-5.75%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.62
$1.82
50-Day Range
$1.08
$1.74
52-Week Range
$0.61
$4.19
Volume
229,679 shs
Average Volume
464,185 shs
Market Capitalization
$80.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.63

CRVS vs. TPST, KRON, GBIO, VHAQ, TRVI, ANVS, KPTI, RLYB, PYXS, and AFMD

Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Tempest Therapeutics (TPST), Kronos Bio (KRON), Generation Bio (GBIO), Viveon Health Acquisition (VHAQ), Trevi Therapeutics (TRVI), Annovis Bio (ANVS), Karyopharm Therapeutics (KPTI), Rallybio (RLYB), Pyxis Oncology (PYXS), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.

Corvus Pharmaceuticals vs.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.

39.8% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.7% of Tempest Therapeutics shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals received 195 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. However, 62.86% of users gave Tempest Therapeutics an outperform vote while only 62.20% of users gave Corvus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Corvus PharmaceuticalsOutperform Votes
283
62.20%
Underperform Votes
172
37.80%
Tempest TherapeuticsOutperform Votes
88
62.86%
Underperform Votes
52
37.14%

In the previous week, Tempest Therapeutics had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Tempest Therapeutics and 0 mentions for Corvus Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 1.07 beat Corvus Pharmaceuticals' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Corvus Pharmaceuticals Neutral
Tempest Therapeutics Positive

Corvus Pharmaceuticals presently has a consensus price target of $6.63, indicating a potential upside of 303.96%. Tempest Therapeutics has a consensus price target of $22.33, indicating a potential upside of 615.81%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than Corvus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Tempest Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Corvus Pharmaceuticals' return on equity of -60.76% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus PharmaceuticalsN/A -60.76% -51.08%
Tempest Therapeutics N/A -378.21%-90.07%

Corvus Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the S&P 500.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$41.31M-$0.64-2.56
Tempest TherapeuticsN/AN/A-$35.71M-$2.20-1.42

Summary

Corvus Pharmaceuticals and Tempest Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.


Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRVS vs. The Competition

MetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$80.43M$5.54B$4.45B$6.63B
Dividend YieldN/A2.78%3.01%4.78%
P/E Ratio-2.5613.04110.6814.13
Price / SalesN/A1,831.682,982.08441.64
Price / CashN/A16.5021.6023.13
Price / Book1.364.333.954.60
Net Income-$41.31M$204.91M$124.09M$177.02M
7 Day Performance9.33%7.39%3.58%2.34%
1 Month Performance10.81%7.90%6.87%6.16%
1 Year Performance57.69%13.92%9.91%6.15%

Corvus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TPST
Tempest Therapeutics
1.8901 of 5 stars
$3.74
-0.8%
$22.33
+497.1%
+96.2%$71.98MN/A-1.7019Positive News
KRON
Kronos Bio
2.2508 of 5 stars
$1.23
-3.1%
$9.00
+631.7%
-24.0%$71.73MN/A-0.5999Gap Down
GBIO
Generation Bio
2.2018 of 5 stars
$1.12
-3.4%
$8.56
+664.1%
-66.9%$74.01MN/A-0.57150Analyst Revision
Gap Up
VHAQ
Viveon Health Acquisition
0 of 5 stars
$11.40
-0.3%
N/A+7.3%$75.81MN/A0.00N/ANews Coverage
TRVI
Trevi Therapeutics
2.4532 of 5 stars
$1.07
-2.7%
$7.00
+557.3%
-46.0%$68.01MN/A-3.9430Positive News
ANVS
Annovis Bio
2.1896 of 5 stars
$7.54
+2.0%
$32.50
+331.0%
-10.2%$77.36MN/A-1.775Gap Up
High Trading Volume
KPTI
Karyopharm Therapeutics
2.0368 of 5 stars
$0.68
-4.2%
$5.86
+762.6%
-83.2%$77.77M$157.07M-0.51385News Coverage
RLYB
Rallybio
1.689 of 5 stars
$2.07
-10.0%
$16.25
+685.0%
-48.2%$78.23MN/A-1.1544Gap Up
High Trading Volume
PYXS
Pyxis Oncology
2.1537 of 5 stars
$1.51
-2.6%
$10.50
+595.4%
+40.5%$66.92MN/A-0.5967Analyst Revision
AFMD
Affimed
2.5226 of 5 stars
$0.52
+15.4%
$5.50
+949.6%
-78.5%$78.25M$43.58M-0.62219Gap Down

Related Companies and Tools

This page (NASDAQ:CRVS) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -